Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Food Chem Toxicol ; 49(6): 1303-15, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21414376

RESUMO

α-Glycerylphosphorylcholine (AGPC) is a semi-synthetic derivative of lecithin. Following oral administration, it is converted to phosphatidylcholine, a metabolically active form of choline that is able to reach cholinergic synaptic endings where it increases acetylcholine synthesis and release. A series of studies were conducted to demonstrate the safety of AGPC. The oral LD50 was equal to or greater than 10,000 mg/kg in rats and mice. Deaths were preceded by convulsions in some animals. Dosing of dogs with up to 3000 mg/kg AGPC resulted only in reduced activity. Sub-chronic and chronic oral toxicity studies in rats (up to 1000 mg/kg/day) and beagles (up to 300 mg/kg/day) produced symptomology primarily consisting of reduced activity; slight decreases in food consumption and body weight gain; and slight reduction in liver weight, paralleled by significant decreases in plasma triglycerides, bilirubin, and alkaline phosphatase. There were no histopathological correlates. The in vivo and in vitro assays clearly indicated that AGPC was devoid of mutagenic activity. Based on these results, AGPC is not genotoxic in vitro or in vivo, exhibits low acute oral toxicity and, has an oral NOAEL of 150 mg/kg bw/day following 26 weeks oral exposure.


Assuntos
Aditivos Alimentares/toxicidade , Inocuidade dos Alimentos , Glicerilfosforilcolina/toxicidade , Administração Oral , Fosfatase Alcalina/sangue , Animais , Bilirrubina/sangue , DNA/efeitos dos fármacos , Cães , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Dose Letal Mediana , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Camundongos , Nível de Efeito Adverso não Observado , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Testes de Toxicidade , Triglicerídeos/sangue , Aumento de Peso/efeitos dos fármacos
2.
Int J Artif Organs ; 30(2): 133-43, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17377908

RESUMO

In this work we synthesized new MDI -based poly(ether)urethanes (PEUs) with phospholipid-like residue as chain extender. Polymers were prepared by a conventional two-step solution polymerization procedure using 4,4' diphenylmethanediisocyanate (MDI) and poly(1,4- butanediol) with 1000 as molecular weight to form prepolymers which were successively polymerized with 1 glycerophosphorylcholine (1-GPC), 2-glycerophosphorylcholine (2-GPC) or glycerophosphorylserine (GPS) as chain extenders. Two reference polymers bearing 1,4-butandiol (BD) have been also synthesized. The polymers obtained were characterized by Fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR), differential scanning calorimetry (DSC) and modulated scanning calorimetry (MDSC). The biocompatibility of synthesized segmented polyurethanes was then investigated by platelet-rich plasma contact studies and related scanning electron microscopy (SEM) photographs for blood compatibility and cytotoxicity assay (MTT test) on material elution to assess the effect of any toxic leachables on cellular viability. Three polymers among all have given very satisfactory results suggesting to investigate more deeply their possible use in biomedical devices.


Assuntos
Materiais Biocompatíveis/química , Glicerilfosforilcolina/química , Fosfosserina/análogos & derivados , Adesividade Plaquetária/efeitos dos fármacos , Poliuretanos/química , Materiais Biocompatíveis/farmacologia , Materiais Biocompatíveis/toxicidade , Glicerilfosforilcolina/farmacologia , Glicerilfosforilcolina/toxicidade , Fosfosserina/química , Fosfosserina/farmacologia , Fosfosserina/toxicidade , Poliuretanos/farmacologia , Poliuretanos/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...